This IC50 dose-response template ships with a 10-step protocol, validated assay references, pre-wired 4-parameter logistic fit fields, and structured inputs for target, compound, dose range, replicate count, Hill slope, IC50, and Z'-factor. Your lab edits the configuration to match the target and inhibitor you actually screen, instead of rebuilding the dose grid every campaign.
This is the live ELabELN experiment view, the same screen your lab works in every day. Switch between a blank start and a fully populated example, then expand any section to see what the template pre-fills.
This IC50 dose-response template ships configured for a kinase inhibitor potency screen against recombinant ERK1 (MAPK3) using the Promega ADP-Glo luminescent kinase assay in 384-well format, with a 10-step protocol covering compound dilution through 4-parameter logistic curve fit and IC50 reporting. The protocol assumes 10-point 3-fold dose dilution from 10 µM to 0.5 nM, 4 replicate wells per dose, recombinant ERK1 at 5 nM final, ATP at the apparent Km (50 µM), MBP substrate at 1 µM, 60-minute kinase reaction, ADP-Glo conversion + detection per vendor protocol, luminescence read on a Synergy Neo2.
Structured fields capture target, compound, assay, and curve-fit metadata in typed inputs (target, target concentration, ATP concentration, compound, high dose, dilution factor, dose points, replicates, IC50, Hill slope, Z'-factor, R²), so dose-response parameters are queryable across compounds and targets instead of buried in free text. Recombinant kinase, ATP, ADP-Glo reagents, substrate, and reference inhibitor link to the ELabELN inventory so lot numbers and aliquot tracking flow into every screen record without manual entry. The spreadsheet editor captures the full dose matrix (dose, replicate luminescence, % activity, normalized inhibition) for direct ingestion into Prism, Python, or R for 4PL curve fitting.
The template is intended as a tested baseline for pharmacology, biotechnology, and CRO labs running compound potency profiling, lead optimization, structure-activity relationship (SAR) studies, and hit-to-lead campaigns. Configure the target (kinase, GPCR, ion channel, enzyme), swap the compound, change the dose range and replicate count, or move from ADP-Glo to alternate detection (HTRF, AlphaLISA, fluorescence polarization, radiometric) by editing the readout section. ELabELN's tamper-evident audit trail captures every screen, every curve fit, and every compound advancement decision, so the resulting record supports lead-compound provenance, FDA 21 CFR Part 11 review, and GLP-relevant preclinical documentation when the lab's quality system requires it.
The template populates the existing ELabELN sections your lab already works with: Main Text, Extra Fields, Steps, Compounds, Links, and more. Your team edits instead of building from scratch.
Screen design, target notes, and expected potency range, written in the TinyMCE editor.
Twelve structured, typed fields grouped by Target, Compound & Dose, and Curve Fit & QC.
Ten-step workflow checklist covering compound dilution through curve fit reporting.
Recombinant kinase, ATP, MBP substrate, ADP-Glo reagents, and reference inhibitor pre-linked from the compound database.
Pre-wired to your lab's IC50 SOPs, kinase datasheet, and prior potency results for this compound series.
Compound aliquots, kinase aliquot tracking, plate-reader CSV exports, and Prism 4PL workbook attachments.
Edit the configuration to match your target and compound series, run the screen from a tested baseline, and capture every dose, every replicate, and every IC50 in a structured record. Browse other templates built for the workflows real labs actually use.
Yes. Every section is editable. Swap in different targets (kinase, GPCR, ion channel, protease, phosphatase, ATPase), change the compound or compound series, adjust the dose range and replicate count, switch the detection method (ADP-Glo, HTRF, AlphaLISA, fluorescence polarization, radiometric, FRET-based), or move from IC50 to EC50 (agonist potency) by editing the curve-fit section. Save your edits as a private template scoped to your lab, or publish back to the ELabELN template library.
The Cell Viability template focuses on cell-based cytotoxicity readouts (MTS, AlamarBlue, CellTiter-Glo) with viability as the endpoint. This IC50 template is target-agnostic and supports biochemical (enzyme inhibition, binding) and cell-based (functional) assays. Use Cell Viability when the readout is cell health; use this template when the readout is target activity (kinase, receptor, channel).
The template captures structured per-well luminescence (or fluorescence, or absorbance), % activity, normalized inhibition, and the 4PL fit parameters (IC50, Hill slope, top, bottom, R²) as typed fields. Curve fitting is performed in your downstream analysis tool (GraphPad Prism, Python with scipy.optimize, R drc package), then the fit parameters are written back into the typed Curve Fit & QC fields for queryable cross-screen comparison.
Yes. Every published template in the ELabELN library is available to all ELabELN subscribers, with unlimited users.
Yes. ELabELN includes unlimited users, so the PI, postdocs, scientists, rotating researchers, and visiting collaborators can all use the template without per-seat charges. Granular permissions let project leads control who can edit screens versus only review them — important during multi-site CRO collaborations.
ELabELN Standard cloud deployment is typically live in 1-2 days. Once the instance is provisioned, this template loads from the library in a single click, with the target, compound, dose range, and detection method editable to match the screens your lab actually runs.